Looking at EU pharmacovigilance

Looking at EU pharmacovigilance

Herxheimer responds to criticism by Garattini and Bertele concerning EU pharmacovigilance. The use of temporary or conditional approvals of new drugs seemed to offer the hope of striking a balance between public interest and commercial pressure, but this hope is not being fulfilled

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical pharmacology 2011-11, Vol.67 (11), p.1201-1202
1. Verfasser: Herxheimer, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Adverse Drug Reaction Reporting Systems - legislation & jurisprudence
Biomedical and Life Sciences
Biomedicine
Common markets
Databases, Factual - legislation & jurisprudence
Legislation, Drug
Open Commentary
Pharmacology
Pharmacology/Toxicology
Pharmacovigilance
Prescription drugs
Product safety
Public health
Regulation
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Herxheimer responds to criticism by Garattini and Bertele concerning EU pharmacovigilance. The use of temporary or conditional approvals of new drugs seemed to offer the hope of striking a balance between public interest and commercial pressure, but this hope is not being fulfilled
ISSN:0031-6970
1432-1041
DOI:10.1007/s00228-011-1074-8